CoreWeave vs Smith & Nephew plc — how do they compare? CoreWeave trades at $82.17 (market cap $44.99B), while Smith & Nephew plc trades at $27.13 (market cap $11.10B). The key difference: CoreWeave is far larger — about 4.1× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while CoreWeave pays none. Which is the better fit depends on your goals — on Pluang, investors hold CoreWeave for 7 Days and Smith & Nephew plc for 121 Days on average.
| CRWV | SNN | |
|---|---|---|
Market Cap | $44.99B | $11.10B |
Volume | 41,993,776 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $143.08 | $37.17 |
52-Week Low | $60.82 | $26.42 |
Typical Hold Time | 7 Days | 121 Days |
Enterprise Value | $91.06B | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CoreWeave provides cloud computing infrastructure designed for AI workloads. Its platform gives organizations access to large-scale GPU computing and cloud services for training and running AI models.
Read more on CRWV →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →